[桑苗药在治疗类风湿性关节炎中的主要活性成分和机制]
Shi-Lin Xia1, Yi Wei1, Xiao-Man Jiang1
1School of Pharmacy, Anhui University of Chinese Medicine Hefei 230012, China.
概括
桑苗药丸 (SMP) 通过影响PI3K/AKT通路,可以治疗类风湿性关节炎 (RA). 这项研究确定了关键组成部分和目标,动物模型证实了SMP.
科学领域:
- 草药研究 草药研究
- 药理学 药理学是指药理学的学科.
- 免疫学 免疫学 免疫学
背景情况:
- 类风湿性关节炎 (RA) 是一种慢性自身免疫性疾病,其特点是关节炎症和破坏.
- 桑苗药片 (SMP) 是一种用于治疗炎症的传统中医药配方.
- 在治疗RA方面SMP的有效性背后的精确分子机制尚未完全阐明.
研究的目的:
- 通过综合方法研究桑米亚药片 (SMP) 在治疗类风湿性关节炎 (RA) 中的潜在治疗机制.
- 为了确定活性化学成分,关键的分子点和参与SMP抗RA作用的信号通路.
- 通过体内动物实验来验证预测的机制.
主要方法:
- 超高性能液态染色学-四极飞行时间质谱学 (UPLC-Q-TOF-MS) 用于SMP的化学分析.
- 网络药理使用DisGeNET和SwissTargetPrediction来识别SMP和RA之间的共同目标.
- 蛋白与蛋白相互作用 (PPI) 网络构建,基因本体学 (GO) 和基因和基因组的京都百科全书 (KEGG) 路径分析.
- 使用二极管阵列检测 (HPLC-DAD) 的高性能液体染色学用于关键活性成分的定量分析.
- 原诱导性关节炎 (CIA) 鼠标模型用于体内验证,包括行为测试,组织学分析和西方 blot.
主要成果:
- 在SMP中,UPLC-Q-TOF-MS确定了126种化学成分. 网络药理学预测了SMP和RA之间的332个重叠目标,AKT1和TNF被确定为关键目标.
- 途径分析突出显示,酸氨基3-激酶 (PI3K) /蛋白激酶B (AKT) 途径显著丰富.
- 通过HPLC-DAD方法验证了五个主要活性成分的含量. 在CIA大鼠中,SMP治疗改善了突细胞增生,并降低了PI3K和酸化AKT (p-AKT) 的表达.
结论:
- SMP 具有多种活性成分,其向关键分子,这些分子与RA 病原发生有关.
- PI3K/AKT信号通路是SMP通过发挥其抗风湿性关节炎作用的关键机制.
- 这项研究为SMP在治疗RA中的临床应用提供了科学基础.
更多相关视频
07:20Author Spotlight: Integrating Traditional Chinese Medicine with Modern Pharmacology and Genomics for Assessing Postmenopausal Osteoporosis in Mice
Published on: August 23, 2024
442
04:47Author Spotlight: Evaluating Traditional Chinese Therapy for Ankylosing Spondylitis in Mice
Published on: October 27, 2023
888
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
141
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
141
Inflammatory Bowel Disease IV: Pharmacological Management
111
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
111
